Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report

A 40-year-old Asian female with heavily treated relapsed Hodgkin's lymphoma showed complete remission (CR) after receiving 8 cycles of brentuximab vedotin (BV) in combination with gemcitabine as 4th line treatment. The patient remained in CR at the 18-month post-treatment follow-up. She develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Purwanto, Ibnu, Utomo, Bambang P., Ghozali, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154270/
https://www.ncbi.nlm.nih.gov/pubmed/32308602
http://dx.doi.org/10.1159/000505830
_version_ 1783521796176216064
author Purwanto, Ibnu
Utomo, Bambang P.
Ghozali, Ahmad
author_facet Purwanto, Ibnu
Utomo, Bambang P.
Ghozali, Ahmad
author_sort Purwanto, Ibnu
collection PubMed
description A 40-year-old Asian female with heavily treated relapsed Hodgkin's lymphoma showed complete remission (CR) after receiving 8 cycles of brentuximab vedotin (BV) in combination with gemcitabine as 4th line treatment. The patient remained in CR at the 18-month post-treatment follow-up. She developed severe hypotension (50/36 mm Hg) with upper and lower limb petechiae and edema after the addition of gemcitabine on the 6th cycle of BV. This adverse event resolved after 3 days of treatment with vasopressor and high-dose corticosteroid. The addition of dexamethasone for the subsequent 2 cycles successfully prevented this adverse event from recurring.
format Online
Article
Text
id pubmed-7154270
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-71542702020-04-19 Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report Purwanto, Ibnu Utomo, Bambang P. Ghozali, Ahmad Case Rep Oncol Case Report A 40-year-old Asian female with heavily treated relapsed Hodgkin's lymphoma showed complete remission (CR) after receiving 8 cycles of brentuximab vedotin (BV) in combination with gemcitabine as 4th line treatment. The patient remained in CR at the 18-month post-treatment follow-up. She developed severe hypotension (50/36 mm Hg) with upper and lower limb petechiae and edema after the addition of gemcitabine on the 6th cycle of BV. This adverse event resolved after 3 days of treatment with vasopressor and high-dose corticosteroid. The addition of dexamethasone for the subsequent 2 cycles successfully prevented this adverse event from recurring. S. Karger AG 2020-03-26 /pmc/articles/PMC7154270/ /pubmed/32308602 http://dx.doi.org/10.1159/000505830 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Purwanto, Ibnu
Utomo, Bambang P.
Ghozali, Ahmad
Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
title Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
title_full Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
title_fullStr Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
title_full_unstemmed Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
title_short Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
title_sort complete remission of relapsed hodgkin's lymphoma following brentuximab vedotin and gemcitabine combination therapy with severe hypotension as possible treatment-related adverse event: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154270/
https://www.ncbi.nlm.nih.gov/pubmed/32308602
http://dx.doi.org/10.1159/000505830
work_keys_str_mv AT purwantoibnu completeremissionofrelapsedhodgkinslymphomafollowingbrentuximabvedotinandgemcitabinecombinationtherapywithseverehypotensionaspossibletreatmentrelatedadverseeventacasereport
AT utomobambangp completeremissionofrelapsedhodgkinslymphomafollowingbrentuximabvedotinandgemcitabinecombinationtherapywithseverehypotensionaspossibletreatmentrelatedadverseeventacasereport
AT ghozaliahmad completeremissionofrelapsedhodgkinslymphomafollowingbrentuximabvedotinandgemcitabinecombinationtherapywithseverehypotensionaspossibletreatmentrelatedadverseeventacasereport

Ejemplares similares